Ranibizumab in monotherapy and combined with photodynamic therapy for retinal angiomatous proliferation

Luis Arias,1–3 Francisco Gómez-Ulla,2–4 José M Ruiz-Moreno2,3,51Ophthalmology Department, Bellvitge University Hospital, C/Feixa Llarga, L’Hospitalet de Llobregat, Barcelona, 2Spanish Vitreoretinal Society (SERV), C/Xosé Chao Rego, Santi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Arias L, Gómez-Ulla F, Ruiz-Moreno JM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Age-related macular degeneration intravitreal injection photodynamic therapy ranibizumab retinal angiomatous proliferation verteporfin. Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/542781159ffc4438b11c5d1aba783e07
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:542781159ffc4438b11c5d1aba783e07
record_format	dspace
spelling	oai:doaj.org-article:542781159ffc4438b11c5d1aba783e072021-12-02T00:37:29ZRanibizumab in monotherapy and combined with photodynamic therapy for retinal angiomatous proliferation1177-5483https://doaj.org/article/542781159ffc4438b11c5d1aba783e072016-05-01T00:00:00Zhttps://www.dovepress.com/ranibizumab-in-monotherapy-and-combined-with-photodynamic-therapy-for--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Luis Arias,1–3 Francisco Gómez-Ulla,2–4 José M Ruiz-Moreno2,3,51Ophthalmology Department, Bellvitge University Hospital, C/Feixa Llarga, L’Hospitalet de Llobregat, Barcelona, 2Spanish Vitreoretinal Society (SERV), C/Xosé Chao Rego, Santiago de Compostela, 3RETICS OFTARED, Institute of Health Carlos III, C/Sinesio Delgado, Madrid, 4Gómez-Ulla Eye Institute, Santiago de Compostela, 5Department of Ophthalmology, Albacete University Hospital, Avenida de Almansa s/n, Albacete, Spain Purpose: To compare the effects of intravitreal ranibizumab in monotherapy (group A) and combined with photodynamic therapy (PDT) with verteporfin (group B) in retinal angiomatous proliferation (RAP) treatment.Methods: This was a multicentric, prospective, randomized clinical study conducted with parallel groups. The study eye in both groups received ranibizumab on days 1, 30, and 60 (loading dose); group B received PDT additionally on day 1. Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) testing and optical coherence tomography were performed monthly, and fluorescein angiography and indocyanine green angiography were performed quarterly. Retreatment criteria were leakage in fluorescein angiography or indocyanine green angiography, mean foveal thickness increase ≥100 µm, or VA decrease ≥5 letters.Results: Twenty patients were recruited (ten patients in each group). Six eyes had previous treatment (three eyes in group A and three eyes in group B), so only 14 eyes were naïve. At 12-month follow-up, mean VA improved +1.5 letters in group A and +5.6 letters in group B (analysis of variance test; P>0.05). Two patients (20%) in both groups gained ≥15 letters (chi-square test; P>0.05). Mean changes in greatest linear dimension and in foveal thickness were not statistically significant between groups of treatment (analysis of variance test; P>0.05). Mean retreatments per patient were 1.8 (group A) and 0.9 (group B) (Mann–Whitney U-test; P>0.05). One patient died due to underlying disease not related to study medication.Conclusion: Intravitreal ranibizumab administered in monotherapy or combined with PDT was efficacious in terms of VA stabilization in patients with RAP.Keywords: age-related macular degeneration, intravitreal injection, photodynamic therapy, ranibizumab, retinal angiomatous proliferation, verteporfinArias LGómez-Ulla FRuiz-Moreno JMDove Medical PressarticleAge-related macular degenerationintravitreal injectionphotodynamic therapyranibizumabretinal angiomatous proliferationverteporfin.OphthalmologyRE1-994ENClinical Ophthalmology, Vol 2016, Iss Issue 1, Pp 861-869 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Age-related macular degeneration intravitreal injection photodynamic therapy ranibizumab retinal angiomatous proliferation verteporfin. Ophthalmology RE1-994
spellingShingle	Age-related macular degeneration intravitreal injection photodynamic therapy ranibizumab retinal angiomatous proliferation verteporfin. Ophthalmology RE1-994 Arias L Gómez-Ulla F Ruiz-Moreno JM Ranibizumab in monotherapy and combined with photodynamic therapy for retinal angiomatous proliferation
description	Luis Arias,1–3 Francisco Gómez-Ulla,2–4 José M Ruiz-Moreno2,3,51Ophthalmology Department, Bellvitge University Hospital, C/Feixa Llarga, L’Hospitalet de Llobregat, Barcelona, 2Spanish Vitreoretinal Society (SERV), C/Xosé Chao Rego, Santiago de Compostela, 3RETICS OFTARED, Institute of Health Carlos III, C/Sinesio Delgado, Madrid, 4Gómez-Ulla Eye Institute, Santiago de Compostela, 5Department of Ophthalmology, Albacete University Hospital, Avenida de Almansa s/n, Albacete, Spain Purpose: To compare the effects of intravitreal ranibizumab in monotherapy (group A) and combined with photodynamic therapy (PDT) with verteporfin (group B) in retinal angiomatous proliferation (RAP) treatment.Methods: This was a multicentric, prospective, randomized clinical study conducted with parallel groups. The study eye in both groups received ranibizumab on days 1, 30, and 60 (loading dose); group B received PDT additionally on day 1. Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) testing and optical coherence tomography were performed monthly, and fluorescein angiography and indocyanine green angiography were performed quarterly. Retreatment criteria were leakage in fluorescein angiography or indocyanine green angiography, mean foveal thickness increase ≥100 µm, or VA decrease ≥5 letters.Results: Twenty patients were recruited (ten patients in each group). Six eyes had previous treatment (three eyes in group A and three eyes in group B), so only 14 eyes were naïve. At 12-month follow-up, mean VA improved +1.5 letters in group A and +5.6 letters in group B (analysis of variance test; P>0.05). Two patients (20%) in both groups gained ≥15 letters (chi-square test; P>0.05). Mean changes in greatest linear dimension and in foveal thickness were not statistically significant between groups of treatment (analysis of variance test; P>0.05). Mean retreatments per patient were 1.8 (group A) and 0.9 (group B) (Mann–Whitney U-test; P>0.05). One patient died due to underlying disease not related to study medication.Conclusion: Intravitreal ranibizumab administered in monotherapy or combined with PDT was efficacious in terms of VA stabilization in patients with RAP.Keywords: age-related macular degeneration, intravitreal injection, photodynamic therapy, ranibizumab, retinal angiomatous proliferation, verteporfin
format	article
author	Arias L Gómez-Ulla F Ruiz-Moreno JM
author_facet	Arias L Gómez-Ulla F Ruiz-Moreno JM
author_sort	Arias L
title	Ranibizumab in monotherapy and combined with photodynamic therapy for retinal angiomatous proliferation
title_short	Ranibizumab in monotherapy and combined with photodynamic therapy for retinal angiomatous proliferation
title_full	Ranibizumab in monotherapy and combined with photodynamic therapy for retinal angiomatous proliferation
title_fullStr	Ranibizumab in monotherapy and combined with photodynamic therapy for retinal angiomatous proliferation
title_full_unstemmed	Ranibizumab in monotherapy and combined with photodynamic therapy for retinal angiomatous proliferation
title_sort	ranibizumab in monotherapy and combined with photodynamic therapy for retinal angiomatous proliferation
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/542781159ffc4438b11c5d1aba783e07
work_keys_str_mv	AT ariasl ranibizumabinmonotherapyandcombinedwithphotodynamictherapyforretinalangiomatousproliferation AT gomezullaf ranibizumabinmonotherapyandcombinedwithphotodynamictherapyforretinalangiomatousproliferation AT ruizmorenojm ranibizumabinmonotherapyandcombinedwithphotodynamictherapyforretinalangiomatousproliferation
_version_	1718403617635958784

Ranibizumab in monotherapy and combined with photodynamic therapy for retinal angiomatous proliferation

Ejemplares similares